A drug used to treat irritable bowel syndrome (IBS) appears to be effective against prostate cancer in mice when given in tandem with chemotherapy, a new study shows. In an article published Jan. 22 ...
PRINCETON, N.J., Jan. 24, 2020 /PRNewswire/ -- SunGen Pharma, a privately held specialty pharmaceutical company which develops, contract manufactures, and sells pharmaceutical finished products, today ...
LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Pharmaceuticals announced today it has received U.S. Food and Drug Administration (FDA) approval for Dicyclomine Hydrochloride (HCl) Injection, USP in ...
Dicyclomine HCl 10mg/mL; soln for IM inj. Inj: avoid IV administration (may cause thrombosis, inj site reactions). Autonomic neuropathy. Hepatic or renal impairment. Cardiovascular disease.
LONDON, May 28, 2020 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational generic pharmaceutical company, has launched Dicyclomine Hydrochloride Oral Solution, USP, 10 mg/5 mL, an ...
Research by a Washington State University-led team of scientists has identified a receptor protein, CHRM1, as a key player in prostate cancer (PC) cells’ resistance to docetaxel (DTX), a chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results